Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature

Akut Promiyelositik Lösemili Bir Hastada t(15;17) ve t(8;21) Birlikteliği: Literatürün Gözden Geçirilmesi

Burak Uz, Eylem Eliaçık, Ayse İşik, Salih Aksu, Yahya Büyükaşık, İbrahim C. Haznedaroğlu, Hakan Göker, Nilgün Sayınalp, Osman İ. Özcebe
Hacettepe University Medical School, Department of Internal Medicine, Division of Hematology, Ankara, Turkey

Abstract:
Additional chromosomal abnormalities in acute myelogenous leukemia have been identified as one of the most important prognostic factors. Favorable chromosomal changes such as t(8;21), inv(16), and t(15;17) are associated with higher rates of complete remission and event-free survival. Translocation (15;17) characterizes acute promyelocytic leukemia (APL) (French-American-British class M3) in almost all patients. Secondary chromosomal abnormalities are also present in approximately 23%-29% of patients with newly diagnosed APL. The prognostic implications of t(8;21) and other secondary cytogenetic aberrations in APL are reviewed here. We present a 47-year-old woman diagnosed with APL whose initial cytogenetic analysis included both t(8;21) and t(15;17). The initial induction chemotherapy included 3 days of idarubicin (12 mg/m²/day) and daily all-trans retinoic acid (45 mg/m²/day). At the sixth week of treatment, a control bone marrow biopsy was found to be normocellular, t(15;17) bcr3 and t(8;21) were negative, and t(15;17) bcr1 fusion transcripts were reduced from 5007 (1.78525699%) copies per 1 µg RNA to 40 (0.00062020%) with real-time quantitative polymerase chain reaction. Consolidation with 4 days of idarubicin (5 mg/m²/day), ATRA (45 mg/m²/day for 15 days), and cytarabine (1 g/m²/day for 4 days) was then started. However, the patient became pancytopenic and had neutropenic fever after consolidation treatment. Unfortunately, she died 3 months after the time of APL diagnosis, due to acute respiratory distress syndrome-like respiratory problems and multiorgan dysfunction requiring respiratory support and hemodialysis.

Key Words: Additional chromosomal abnormalities, Acute promyelocytic leukemia

Özet:
Ek kromozomal anomaliler en önemli prognoistik faktörlerden biri olarak belirlenmiştir. Translokasyon t(8;21), ve t(15;17) gibi olumlu kromozomal değişiklikler daha yüksek tam remisyon ve olaysız sağkalım ile ilişkilidir. Translokasyon (15;17) neredeyse tüm hastalarda akut promiyelositik lösemiyi (APL) tanımlamaktadır (Fransız-Amerikan-İngiliz [FAB] sınıf M3). Yeni tanı alan APL hastalarının yaklaşık %23-29'unda ikincil kromozomal anomaliler de bulunmaktadır. Bu olguUTESAGILEYAP'cde t(8;21) ve diğer ikincil sitogenetik aberasyonların prognoistik etkileri gözden geçirilmiştir. APL tanısı konan 47 yaşındaki kadın hastanın tanı anındaki sitogenetik analizinde t(8;21) ve t(15;17) birlikteliği saptandı. Başlangıç indüksiyon kemoterapisi 3 gün idarubisin (12 mg/m²/gün), ve günlük all-trans retinoik asit (ATRA) (45 mg/m²/gün) içermekteydi. Tedavinin 6. haftasında yapılan kontrol kemik iliği biopsy normoselülerdi. t(15;17) bcr3 ve t(8;21) negatifti, ve gerçek zamanlı kanıtlanan polimeraz zincir reaksiyono (RQ-PCR) ile tespit edilen t(15;17) bcr1 füzyon transkriptleri 5007 (1,78525699 %) kopya/1 µg RNA'dan 40 (0,00062020 %)'a düştü. Bunun üzerine 4 gün idarubisin (5 mg/m²/gün), 15 gün ATRA (45 mg/m²/gün), ve 4 gün sitarabin (1 g/m²/gün) içeren konsoldasyon tedavisi başlandı. Konsoldasyon tedavisi sonrasında hastada pansitopeni ve nötropenik atış tablosu gelişti. APL tansından 3 ay sonra, solunum desteği ve hemodiyaliz gerektiren çoklu organ fonksiyon bozukluğu ve ARDS-benzeri solunum problemleri nedeniyle hasta kaybedildi.

Anahtar Kelimeler: Ek kromozomal anomaliler, Akut promiyelositik lösemi
Introduction

Acute promyelocytic leukemia (APL) accounts for approximately 10%-15% of acute myelogenous leukemia (AML) cases and is a very specific subtype with regard to morphologic, clinical, and prognostic features [1]. Although APL has the highest frequency of hemorrhagic morbidity and mortality among all subtypes of AML, most patients with t(15;17) will respond to a combination treatment with all-trans-retinoic acid (ATRA), cytarabine (Ara-C), and anthracycline-based chemotherapy [1,2].

Balanced chromosome rearrangements are detected in approximately 25%-30% of adults with de novo AML [3-5] and have attracted a great deal of attention because of specific translocations and inversions associated with the prognosis of the patients harboring them. t(15;17) is known to be found in almost all APL patients [1]. Chromosomal abnormalities accompanying t(15;17) are reported in 23%-39% of APL cases [2,6,7,8,9,10]. Additional chromosome rearrangements including t(8;21) and t(15;17) are rarely seen in APL patients [11,12]. However, the clinical impact of these secondary anomalies has not been clearly elucidated yet.

Herein, we present an APL patient who had both t(15;17) and t(8;21) at the time of diagnosis. Diagnosis of APL in this patient was based on karyotyping, immunophenotyping, and molecular studies of bone marrow cells. The treatment and clinical course of the patient is summarized. Informed consent was obtained.

Case Report

In February 2012, a 47-year-old woman was admitted to the General Surgery Department of our institution with a 3-week history of fever, anal pain, and rectal discharge. Her initial blood count showed pancytopenia as follows: Hb, 55 g/L (normal range: 117-155), WBC: 1.6 x 10^9/L (normal range: 4.1-11.2) with 0.2 x 10^9/L absolute count (10.4%) of neutrophils, and platelets, 56 x 10^9/L (normal range: 159-388). Peripheral blood smear revealed 1% neutrophils, 11% lymphocytes, 88% lymphomononuclear cells, poikilocytosis, anisocytosis, and schistocytes. Besides a mild increase in fasting blood glucose (6.56 mmol/L; normal range: 3.9-6.1), all biochemical parameters were within normal limits. Abdominal magnetic resonance imaging (MRI) revealed a lesion consistent with abscess formation (1.8 x 1.3 cm) adjacent to the right of the anal canal, which was hyperintense in T2A-weighted images and demonstrated peripheral involvement after the administration of intravenous contrast medium. A lateral internal sphincterotomy was performed in March 2012. After the operation she had continuous fever and leukocytosis (21.8 x 10^9/L) with 19.6 x 10^9/L absolute count (89.9%) of neutrophils. Her platelet count decreased to 11 x 10^9/L. Despite replacement with platelet suspensions, she had retinal bleeding. Coagulation parameters revealed a

Increased prothrombin time (2.22 international normalized ratio; normal range: 0.86-1.20), D-dimer level (>20 mg/mL; normal range: 0.48), and thrombin time (27.2 s; normal range: 16.6-22.5). Fibrinogen level was found to be low (1.4 µmol/L; normal range: 6.4-11.9). Activated partial thromboplastin time was normal. The patient was referred to the hematology division. Her physical examination revealed fever (38.3 °C), generalized petechiae, and bilateral complete loss of pupillary light reflex. She did not have a chronic disease or history of drug usage. She had been pancytopenic since December 2011, and a bone marrow biopsy performed at another center was found to be normocellular (50%), with no finding of dysplasia. The bone marrow biopsy was repeated to reveal a marked increase in cellularity, with a grade I-II/III increase in reticulin network. Intermediate- to large-sized immature cells with large cytoplasm and irregularly shaped nuclei including light chromatin and 2-3 little nucleoli were seen. The immature cells were CD34-negative. Immature cells were accepted as Faggot cells including Auer rods with May-Grünwald Giemsa staining. Bone marrow aspiration revealed 20% blasts and 20% promyelocytes. Thus, the patient’s diagnosis was APL. Spinal lumbosacral MRI showed diffuse bone marrow signal alterations and contrast medium involvement of all vertebrae and iliac bones. A suspicious compression at the L5 level was also reported, but the patient did not have any neurologic deficits.

Flow cytometric analysis of bone marrow samples identified the presence of an abnormal population of CD13(+)/CD33(+)/CD45(+)/MPO(+)/DR(-)/Tdt(-) cells. Analysis of 25 metaphases showed clonal abnormalities. The karyotype was interpreted as 46,XX,t(8;21)(q22;q22) [1]/46,XX,t(15;17)(q22;q21) [5]/46,XX[24]. Additional fluorescence in situ hybridization (FISH) studies for the PML locus at 15q22 and RARα locus at 17q21 were carried out. Analysis of 100 interphase nuclei showed a hybridization pattern consistent with PML/RARα fusion in 36 (36%) nuclei (nuc ish(PMLx3)(RARA(fax3))(PML conRARA(fax1) [36/100]). In addition, real-time quantitative (RQ) polymerase chain reaction (PCR) analysis with t(15;17) bcr1 transcript revealed 5007 copies (1.78525699%) of fusion transscripts per 1 µg RNA and 305 copies (0.108256554%) of fusion transcripts per 1 µg RNA with t(15;17) bcr3 transcript. FLT3 ITD and D835 mutations were studied from peripheral blood with the PCR and restriction fragment length polymorphism (PCR-RFLP) method, and both were negative.

Induction chemotherapy consisting of 3 days of idarubicin (12 mg/m^2/day) and daily ATRA (45 mg/m^2/day) was initiated. After the induction therapy, the pancytopenic state improved (Hb: 10 g/L, WBC: 3.6 x 10^9/L with 2.1 x 10^9/L absolute count (59.0%) of neutrophils, platelets: 239 x 10^9/L), and the hemostasis tests returned to normal limits except a mild increase in D-dimer (2.02 mg/mL)
and fibrinogen levels (15.6 μmol/L). At the sixth week of treatment, a control bone marrow biopsy was found to be normocellular. In addition, t(15;17) bcr3 and t(8;21) were negative, and t(15;17) bcr1 fusion transcripts were reduced from 5007 (1.78525699%) copies per 1 µg RNA to 40 (0.00062020%). Consolidation treatment including 4 days of idarubicin (5 mg/m²/day), ATRA (45 mg/m²/day for 15 days), and cytarabine (1 g/m²/day for 4 days) was then started. After consolidation therapy, the patient became pancytopenic and had neutropenic fever. She was transferred to the intensive care unit because of acute respiratory distress syndrome-like respiratory problems and multiorgan dysfunction requiring hemodialysis and respiratory support. Despite appropriate antibiotic treatment, multiple red blood cell and platelet transfusions, and inotropic agents, the patient expired 3 months after the time of APL diagnosis.

Discussion

In the APL-93 trial, the incidence of chromosomal abnormalities in addition to t(15;17) was 26%, and trisomy 8 was the most frequent secondary change (46% of the cases with secondary changes) [2]. Additional chromosome rearrangements including t(8;21) and t(15;17) are rarely seen in APL patients treated initially with ATRA plus chemotherapy [11,13,14,15]. Two case studies reported a coexistence of t(8;21) and t(15;17) chromosomal anomalies in their patients at the time of diagnosis, and they concluded that t(8;21) may have been the first event to originate from an early leukemic clone, while t(15;17) was acquired later in the course of the disease [11,13]. Charrin et al. detected 2 clones at the initial phase of an AML including 46.XX,t(15;17) and 46.XX,t(8;21),t(15;17). Relapse occurred after 12 months of complete remission with typical APL syndrome when t(15;17) alone was the most predominant [11]. Movafagh et al. [16] reported a female patient in whom 2 French-American-British (FAB)-specific chromosome aberrations evolved from a single leukemic clone and co-expressed t(15;17) and t(8;21). Recently, in a case of APL-M3v in which complete remission was achieved soon after a course of ATRA plus chemotherapy, a novel t(8;21) chromosomal aberration was detected from 3 to 18 months after initial treatment. Intermittent detection of t(8;21) during periods without ATRA therapy may reflect the antitumor effect of ATRA on M2 leukemic cells and 2 independently growing aberrant stem cell clones in this patient. The authors also suggested that the proportion of M2 leukemic cells at the time of diagnosis should be below the sensitivity level of the nested PCR detection limit, and, after chemotherapy, alteration of bone marrow cell kinetics should trigger t(8;21) via complex mechanisms [12].

The prognostic impacts of additional cytogenetic abnormalities in APL patients have been analyzed in a number of studies, and conflicting results were obtained [2,6,7,8,9,10]. Grimwade et al. evaluated 1612 AML patients and found that these cytogenetic changes did not alter the prognosis of patients with favorable karyotypic anomalies such as t(15;17). Trisomy 21 was categorized in the intermediate risk group, while monosomies 5 and 7 had no effects on response rates and overall survival [10]. In the largest study by de Botton et al. [2], patients with only t(15;17) and patients with t(15;17) plus other chromosomal abnormalities were compared. In accordance with the findings of Grimwade et al. [10], additional cytogenetic changes in patients with t(15;17) had no impact on complete remission rate, event-free survival, relapse and overall survival at 2 years. Calabrese et al. suggested that complex chromosome translocations were secondary changes that occurred after standard t(8;21) and t(15;17), thus clarifying the hierarchy of the cytogenetic events [17].

Today, ATRA in combination with conventional chemotherapy increases the efficacy of ATRA dramatically and improves the long-term survival of APL patients to 75% [18]. In non-APL AML, the effects of ATRA are less clear. However, there has been a long-standing interest in the clinical use of ATRA for the treatment of AML subtypes other than APL. ATRA has growth inhibitory effects in non-M3 leukemic cells through cytotoxicity and apoptosis [19]. ATRA's inhibitory roles in non-APL leukemic cells including the HL-60 cell line [20], ovarian carcinoma, neuroblastoma, and germ cell tumors [21] were also reported. Based on these promising scientific data, Schlenk et al. evaluated ATRA in combination with intensive chemotherapy in non-APL elderly AML patients. They suggested that patients with the genotype mutant NPM1 without FLT3 ITD who had been randomized to the ATRA arm had a significantly better relapse-free and overall survival compared to patients with the same genotype who had not been randomized to the ATRA arm. They considered that ATRA may exert its effect by down-regulation or by posttranslational modification of the antiapoptotic protein bcl-2 [22]. Four cases of AML that were initially misdiagnosed as APL based on FAB classification were successfully treated with ATRA alone. Three of these patients achieved complete response (CR), but all of them relapsed early. Their diagnoses were changed to t(8;21) AML based on karyotype analysis. One of the 3 patients who achieved CR had a decrement of the AML1-ETO fusion gene from 92% to 0% after 10 days of ATRA treatment. However, prior use of arsenic trioxide in the same patient did not alter the AML1-ETO fusion gene in the bone marrow cells according to FISH analysis. Interestingly, one patient who had a temporary response (without CR) with ATRA achieved CR after a combined treatment including daunorubicin and cytarabine. The presence of both AML1-ETO and PML-RARα fusion genes were detected by RT-PCR in this patient [23]. The authors suggested that AML1-ETO and PML-RARα recruit a multiprotein complex containing histone deacetylases (HDACs) on crucial myeloid differentiation via several co-repressors, which leads to a cell differentiation block [24]. In addition, oligomerization and
formation of high-molecular-weight complexes by AML1-ETO and PML-RARα play a critical role in the aberrant recruitment of HDAC activity [25].

Our case showed the typical APL morphology and co-expression of t(8;21) and t(15;17), which was detected by conventional cytogenetic analysis. RQ-PCR technology has recently reached a level of sensitivity, accuracy, and practical ease that supports its use as a routine bioinstrumentation for gene level measurement [26]. However, in our patient, t(8;21) was determined by cytogenetic analysis, but not by RQ-PCR. FLT3 ITD and DBS3 mutations were both negative. Classic AIDA induction chemotherapy [27,28] was administered to the patient. She went into remission after induction chemotherapy. t(15;17) bcr3 and t(8;21) became negative, and t(15;17) bcr1 fusion transcripts were reduced from 5007 (1.78525699%) copies per 1 µg RNA to 40 (0.00062020%) according to RQ-PCR. Consolidation treatment including 4 days of idarubicin (5 mg/m²/day), ATRA (45 mg/m²/day for 15 days), and cytarabine (1 g/m²/ day for 4 days) was then started.

Co-expression of t(8;21) and t(15;17) is rarely seen in APL patients. The role of chromosome translocations other than t(15;17) in APL is still unclear. The current literature data support the concept that patients harboring t(15;17) with any other additional chromosomal abnormality a similarly favorable prognosis as patients with t(15;17) alone. Combined use of conventional cytogenetics, FISH [29], and PCR should increase the detection of additional chromosomal abnormalities either in diagnosis or in the treatment period of APL. Combination therapy with ATRA, Ara-C, and anthracycline should be an appropriate choice to improve the prognosis in these patients. Further studies are required to clarify the clinical features and prognosis with complex translocations.

Conflict of Interest Statement

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Saydam G. [Acute promyelocytic leukaemia]. Turkiye Klinikleri J Med Sci 2007;3:42-49.
2. de Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconnick E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P; European APL Group. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000;111:801-806.
3. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;15:100:4325-4336.
4. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paetta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of premission and postremission therapy in adult acute myeloid leukaemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-4083.
5. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C, Wheatley K, Burnett AK, Goldstone AH; Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukaemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
6. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, Löffler H, Büchtner T, Fonatsch C. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol 1996;94:493-500.
7. Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukaemia—Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol 1997;15:1786-1795.
8. Hoorn LS, Swansbury JG, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997;96:314-321.
9. Pantic M, Novak A, Marisavljevic D, Djordjevic V, Elezovic I, Vidovic A, Colovic M. Additional chromosome aberrations in acute promyelocytic leukaemia: characteristics and prognostic influence. Med Oncol 2000;17:307-313.
10. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2002;94:493-500.
11. Charrin C, Ritouet D, Campos L, Devaux Y, Archimbaud E, Fraise J, Fiore D, Germain D. Association of t(15;17) and t(8;21) in the initial phase of an acute promyelocytic leukaemia. Cancer Genet Cytogenet 1992;58:177-180.
12. Neto WK, Serpa M, Sanabani SS, Bueno PT, Velloso ED, Dorflia-ac-Llacer PE, Bendit I. Early detection of t(8;21) chromosomal translocations during treatment of PML-RARA positive acute promyelocytic leukemia: a case study. Clin Med Insights Oncol 2010;4:163-170.

13. Bonomi R, Giordano H, del Pilar Moreno M, Bodega E, Landoni AI, Gallagher R, del Rosario Uriarte M. Simultaneous PML/RARα and AML1/ETO expression with t(15;17) at onset and relapse with only t(8;21) in an acute promyelocytic leukemia patient. Cancer Genet Cytogenet 2000;123:41-43.

14. Varella-Garcia M, Brizard F, Roche J, Flandrin G, Drabkin H, Brizard A. AML1/ETO and PMl/RARA rearrangements in a case of AML-M2 acute myeloblastic leukemia with t(15;17). Leuk Lymphoma 2001;15:1359-1368.

15. Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C, Gao YR, Niu C, Cao Q, Gu BW, Zhu YM, Gu J, Hu J, Yan H, Shen ZX, Chen Z, Chen SJ. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia 2001;15:1359-1368.

16. Movafagh A, Varma N, Varma S. Co-expression of two FAB-specific chromosome changes, t(15;17) and t(8;21), in a case of acute promyelocytic leukemia. Ann Hematol 1996;72:375-377.

17. Calabrese G, Min T, Stuppia L, Powles R, Swansbury JG, Morizio E, Peila R, Donzi E, Fioritoni G, Palka G. Complex chromosome translocations of standard t(8;21) and t(15;17) arise from a two-step mechanism as evidenced by fluorescence in situ hybridization analysis. Cancer Genet Cytogenet 1996;91:40-45.

18. Degos L, Wang ZY. All trans-retinoic acid in acute promyelocytic leukemia. Oncogene 2001;20:7140-7145.

19. Lehmann S, Bengtzen S, Broberg U, Paul C. Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML. Leuk Res 2000;24:19-25.

20. Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009;16:84-91.

21. Miller WH Jr. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998;83:1471-1482.

22. Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groser S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H. German-Austrian AML Study Group (AMLSG). Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009;94:54-60.

23. Qian SX, Li JY, Hong M, Qiu HR, Fan L, Xu W. Acute myeloid leukemia in four patients with t(8;21) treated with all-trans retinoic acid as a single agent. Leuk Lymphoma 2008;49:998-1001.

24. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 co-repressors. Mol Cell Biol 1998;18:7176-7184.

25. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000;5:821-830.

26. Savli H, Hatırnaz Ö. [Quantitative real time-polymerase chain reaction and gene expression analysis in haematology: a review]. Türkiye Klinikleri J Med Sci 2004;24:653-660.

27. Sanz MA, Martin G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol MJ, González JD, Colomer D, Chillón C, Rivas C, Gómez T, Ribera JM, Bornstein R, Román J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARA-positive acute promyelocytic leukemia. PETHEMA Group. Blood 1999;94:3015-3021.

28. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, Gonzalez J, Diaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, Gonzalez JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115:5137-5146.

29. Öğur G, Fen T, Sucak G, Heimann P, Cankuş G, Haznedar R. Impact of fluorescence in situ hybridization in the detection of cryptic fusion transcript PML/RARA and a complex t(5;15;17) in a case of acute promyelocytic leukemia. Turk J Haematol 2000;17:207-212.